FDA grants breakthrough therapy designation to Ifinatamab Deruxtecan for lung cancer patients
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Subscribe To Our Newsletter & Stay Updated